Baseline NT‐proBNP Accurately Predicts Symptom Response to Transcatheter Aortic Valve Implantation

Background Up to 30% of patients undergoing transcatheter aortic valve implantation (TAVI) experience minimal symptomatic benefit or die within 1 year, indicating an urgent need for enhanced patient selection. Previous analyses of baseline NT‐proBNP (N‐terminal pro‐brain natriuretic peptide) and TAV...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christopher J. Allen, Jubin Joseph, Tiffany Patterson, Matthew Hammond‐Haley, Hannah Z. R. McConkey, Bernard D. Prendergast, Michael Marber, Simon R. Redwood
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2020-12-01
Edice:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Témata:	aortic stenosis NT‐proBNP transcutaneous aortic valve implantation transfemoral aortic valve implantation
On-line přístup:	https://www.ahajournals.org/doi/10.1161/JAHA.120.017574
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!